Cabaletta Bio is trading at $3.50 (+6.21%), with broader biotech strength providing the clearest near-term context.

  • XBI is up 2.75%, alongside the gain.
  • No new company-specific catalyst was confirmed on September 2; the September 1 announcement only covered upcoming investor conferences.